Why Inhibrx Biosciences, Inc.’s (INBX) Stock Is Down 11.14%
As of Friday, July 10, Inhibrx Biosciences, Inc.’s INBX share price has dipped by 11.14%, which has investors questioning if this is right time to buy.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Commentary & Analysis
Why Inhibrx Biosciences, Inc.’s (INBX) Stock Is Down 5.58%
As of Friday, July 10, Inhibrx Biosciences, Inc.’s INBX share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Inhibrx Biosciences, Inc.’s (INBX) Stock Is Up 6.97%
As of Thursday, July 09, Inhibrx Biosciences, Inc.’s INBX share price has surged by 6.97%, which has investors questioning if this is right time to sell.Michael Rose
Why Inhibrx Biosciences, Inc.’s (INBX) Stock Is Down 5.80%
As of Tuesday, June 02, Inhibrx Biosciences, Inc.’s INBX share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Inhibrx Biosciences, Inc.’s (INBX) Stock Is Down 8.47%
As of Friday, May 15, Inhibrx Biosciences, Inc.’s INBX share price has dipped by 8.47%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | INBX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,243.1 | $251.9 | 48% |
|
| Shares Out (Mil) | 15.6 | 50.8 | 27% |
|
| Institutional Ownership | 80.0% | 92.0% | 49% |
|
| Float (Mil) | 8.4 | 40.5 | 17% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 218 | 447 | 46% |
|
| Price Change (52-week) |
249.3% | 54.2% | 98% |
|
| Growth | INBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (9.8%) | na |
|
| EPS (5yr) | na | 16.3% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($2.280) | ($9.260) | ($6.300) | |
| Month Ago EPS | ($2.280) | ($9.260) | ($6.300) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($1.340) | ($5.460) | ($2.790) | |
| Year/Year Chg | 6.2% | 2.4% | (41.5%) | |
| Financials | INBX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $39 | 2% |
|
| Net Income (TTM) (Mil) | ($130) | ($43) | 9% |
|
| EPS (TTM) | ($8.390) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($132) | ($30) | 5% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $179 | $5 | 49% |
|
| Enterprise Value (Q1) (Mil) | $1,613 | $182 | 47% |
|
| Valuation | INBX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.60 | na |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | INBX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (61.0%) | (49.7%) | 10% |
|
| ROE | (354.7%) | (55.4%) | 2% |
|
| Liabilities to Assets | 111.4% | 30.3% | 95% |
|
| F-Score | 2 | 3 | 7% |
|
Inhibrx Biosciences, Inc. did not pass any screens on 7/30/2026.
